The effect of clotrimazole on prevention of Otomycosis.
Phase 2
- Conditions
- Otomycosis.B36.9
- Registration Number
- IRCT2015040513136N3
- Lead Sponsor
- Vice Chancellor for Research of Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Inclusion: Otomycosis (Direct examination, or sometimes culture result).
Exclusion criteria: Tympanic perforation.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence. Timepoint: 3 month. Method of measurement: Patient complaints and clinical examination.
- Secondary Outcome Measures
Name Time Method one. Timepoint: None. Method of measurement: None.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie clotrimazole 1% efficacy in preventing otomycosis recurrence?
How does clotrimazole 1% compare to standard antifungal treatments like amphotericin B for otomycosis prevention?
Are there specific fungal biomarkers that predict response to clotrimazole in otomycosis patients?
What adverse events are reported with clotrimazole 1% for otomycosis recurrence prevention and their management?
What combination therapies with clotrimazole show enhanced efficacy against otomycosis recurrence in phase II trials?